Graeme Bell

https://wearewaiv.com Waiv exists to catalyze precision medicine with clinical-grade, AI-powered tests that accelerate biomarker discovery and detection, outcome prediction, and treatment-response assessment across oncology. Built on over seven years of validated medical-AI innovation and one of Europe’s largest multi-institutional data networks, Waiv delivers precise, accurate, and fast analyses that support treatment decisions. Waiv collaborates with global pharmaceutical companies, research institutions, diagnostic organizations and healthcare systems to bring scalable precision medicine to patients worldwide. Waiv is backed by OTB Ventures and Alpha Intelligence Capital (AIC), with participation from Serena Data Ventures, Karista, and SistaFund, with an initial financing of $33 million dollars to expand its clinical testing solutions and fuel commercial expansion.

Our Company We are a special purpose acquisition company incorporated as a Cayman Islands exempted company and incorporated for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this prospectus as our initial business combination. We have not selected any business combination target, and we have not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with any business combination target. We may pursue an initial business combination target in any business or industry. While we may pursue an acquisition opportunity in any business industry or sector, we intend to capitalize on the ability of our management team to identify, acquire and manage a business at the intersection of technology and health that can benefit from our operational expertise. Members of our management team and Averin Capital personnel have significant experience founding, building and scaling businesses in the health and technology ecosystems. Our sponsor is an affiliate of Averin Capital. Averin Capital is a company creation and multi-stage investment firm focused on transformative technologies at the intersection of health and technology. Averin Capital invests across key verticals including artificial intelligence, longevity, data-driven care, and deep technology, with a mission to accelerate innovations that improve human health and extend long-term well-being. Averin applies a collaborative approach, combining scientific rigor, operational expertise, and strategic insight to help visionary teams scale and create lasting impact. As operators, founders, innovators, and investors, Averin seeks to work closely with management teams with the goal of driving growth.

https://www.mindstate.design.com Unlocking safe & reliable access to a wider range of emotional and cognitive states Mindstate Design Labs is a clinical-stage AI neuroengineering platform company developing novel classes of psychoactive therapeutics for psychiatric indications with high unmet need. The company’s Osmanthus platform maps the molecular biology underlying emotion, perception, and cognition to identify how specific neurotransmitter system interactions produce distinct emotional and cognitive states. Lead Asset: MSD-001 currently in human studies to demonstrate that profoundly therapeutic emotional and cognitive states can be precision-designed. MSD-001 is a pharmaceutical compound that can temporarily enable significant emotional & cognitive flexibility. ‍ The Company is developing multiple combinations with the base ingredient of MSD-001. Each combination is built to reliably induce a state like empathy, awe, or enhanced aesthetic perception - offering new therapeutic possibilities to transform our deepest psychological afflictions.

https://www.owkin.com Understanding complex biology through AI Owkin is an agentic AI company on a mission to explore complex biology to speed up and scale research for the creation of new treatments and diagnostics for patients. Owkin K, our AI co-pilot combines unparalleled access to multimodal data, cutting-edge AI to quantify biology and pioneering agentic AI to achieve Biological Artificial Superintelligence in the future. Owkin, a leading agentic AI company, has launched K Navigator, an AI-powered research co-pilot designed to revolutionize biomedical science. K Navigator is an agentic playground where researchers can explore, refine, and validate hypotheses, accelerating the quality and pace of their discoveries. With K Navigator, Owkin moves closer to its vision of developing the world’s first Biological Artificial Superintelligence (BASI). A single natural language interface - K Navigator enables users to explore and visualize data, refine questions, and uncover insights with ease. It accelerates literature reviews across 26.5 million scientific articles, reveals unexplored and unpublished research areas, and delivers more accurate analysis, drawing on 19 biomedical databases featuring thousands of patients.

https://sbxhealth.com A blockchain-powered B2B health data exchange that empowers health systems to securely unlock and share data, driving advancements in medical research. A blockchain-enabled data exchange that health systems trust in: DATA TRANSPARENCY: All transaction stored on blockchain’s decentralized network for transparency and auditability. DATA OWNERSHIP: Creating a value for data owners and utilizing digital smart contracts to ensure owners remain in control of their data assets. DATA PRIVACY: We provide unique privacy preserving solutions to address your local regulations. DATA AGGREGATION: Curation of data into desired interoperable formats to improve data efficiency. Symbiotix has become the trusted data sharing partner for global health systems and provides a solution to access previously unattainable patient data.

Academic Institution known for Entrepreneurship https://www.lusep.co.uk https://www.lusep.co.uk/lu-inc Demonstrated commitment to investing in & developing next-generation entrepreneurs. Startup mentor:- As part of Loughborough University Science & Enterprise Park (LUSEP), located in England, I support Loughborough University Incubator (LUinc) helping launch innovative start-ups, spin-outs, and social entrepreneurs. Working with cutting-edge startups/spin-outs, supporting student entrepreneurs with financial strategy and business planning. This mentorship, associated with the entrepreneurship program, involves periodic, quarterly, meetings with university student entrepreneurs, typically conducted in the evenings or weekends.

Founder & CEO of own agency providing advisory services and new business incubation. Advisory services providing corporate strategy, deals and fundraising, due diligence, and product development for biotech and pharma companies.

https://micregen.com Who we are:- Micregen’s goal is to prolong the period of quality active life by targeting degenerative or deteriorating processes leveraging its proprietary Secretomix® platform to develop advanced therapeutics. These biologics, secreted from stem cells, have shown potential in pre-clinical studies addressing numerous inflammatory and degenerative conditions. We are poised to make significant advancements in the biotechnology sector with our novel approach and robust pipeline. Clinical manufacture is underway in readiness for a strategically chosen clinical trial. What we do:- Micregen has developed an advanced platform technology to create stem cell derived cell-free therapeutics. These multifactorial and multipotent biologics, produced through Micregen’s proprietary methods – Secretomix®, may offer diverse therapeutic effects such as inflammation modulation, enhanced cellular proliferation and migration, reduced cellular senescence, and improved tissue repair and regeneration. The company's innovative approach allows it to target a wide range of degenerative diseases and ageing associated dysfunctions within different systems of the body. Business Model:- Micregen’s business model focuses on the development and commercialisation of stem cell-derived secretomes for treating a variety of diseases with shared pathology i.e. diseases of prematurity, degeneration and ageing-associated diseases. In executing our business model, we intend to leverage strategic partnerships, medical education, collaborations with key opinion leaders and patient advocacy groups to drive market penetration and adoption of its therapeutics.

Biotech company working on CV19 and respiratory viral prophylaxis

https://www.valohealth.com

Valo is a new type of technology company, uniting human and machine intelligence aiming to accelerate the creation of life-changing treatments. We have created the first closed-loop, human-centric, active-learning, end-to-end integrated drug discovery and development engine. Driving the strategy of a new technology company where every aspect of discovering and developing therapeutics is optimized with human-centric data-driven technologies. Accelerating critical life changing therapeutic assets by leading and managing corporate finance to execute the strategy including resource allocation, disease area focus and programmatic M&A. Inspired by our patients to ask the question, "What if ..." This is Intelligent Health.

Obtained Fellowship in 2000